Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracervical Vasopressin for Hysteroscopic Removal of RPOC
NCT07102615Phase 4Recruiting
- Sponsor
- Prisma Health
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of vasopressin in retained products of conception (RPOC) (2 arms), sponsored by Prisma Health. Primary endpoint: Completion of procedure hysteroscopically. Started Oct 2025; status: recruiting.
02
Drugs
vasopressin
03
Conditions
retained products of conception (RPOC)
Beyond the preview
Go deeper on NCT07102615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07102615.